BMO Capital Defends Tourmaline Bio (TRML): 'Why We Think PhII Data Is a Win; Stock Reaction Overblown'
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $35.00 price target on Tourmaline Bio (NASDAQ: TRML).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
